ReviewJournal of Cancer2019
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology.
Review in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies.Journal of cancer survivorship : research and practice · 2024Pooled it
- Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials.Frontiers in oncology · 2024Pooled it
- A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis.Cardiovascular and interventional radiology · 2022Pooled it
- Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model.Journal of pharmacokinetics and pharmacodynamics · 2022Pooled it
- Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study.International journal of cancer · 2026Trial
- A clinical-radiomic model based on best subset regression for prognostic prediction in natural killer/T-cell lymphoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Review
- Role of the Wnt5A pathway in resistance to immune checkpoint inhibitors in advanced Non-Small Cell Lung Cancer.Cancer immunology, immunotherapy : CII · 2026Article
- The evolving global landscape of first-in-class oncology drug innovation.Signal transduction and targeted therapy · 2026Review
- ESIRA, a novel framework integrating efficacy and safety for evaluating first-line treatments in advanced hepatocellular carcinoma.Science China. Life sciences · 2026Article
- Present and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Does Treatment of Jaundice Matter before Pancreaticoduodenectomy? Results from an International Multicentre Recurrence after Whipple (RAW) Study.European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes · 2026Observational
- Impact of adjuvant immunotherapy on prognosis in esophageal squamous cell carcinoma patients following neoadjuvant immunochemotherapy.Frontiers in oncology · 2026Article
- Long-term efficacy of traditional Chinese medicine combined with chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of reconstructed individual patient data over 3 years.Frontiers in pharmacology · 2026Review
- Telomerase inhibitors TMPyP4 and BIBR 1532 show synergistic antitumor activity in combination with chemotherapeutic drugs.Scientific reports · 2025Article
- Management of Isolated Axillary Recurrence in Breast Cancer: Is There a Role for Targeted Axillary Dissection?Cureus · 2025Article
- First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors.Journal of the National Cancer Institute · 2025Article
- Understanding characteristics of contemporary cancer survival for modelling the cost-effectiveness of new interventions.BMJ oncology · 2025Article
- Epidemiological Profile of Adult Hematopoietic Stem Cell Transplantation for Malignant Diseases: Experience from a Reference Service in Urmia, Iran (2010-2024).Medical journal of the Islamic Republic of Iran · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.